NewAmsterdam Pharma (NAMS) Intangibles (2022 - 2023)
NewAmsterdam Pharma's (NAMS) quarterly Intangibles came in at $88887.8 in Q2 2023, down 99.9% quarter-over-quarter from $84.8 million in Q4 2022.
NewAmsterdam Pharma (NAMS) Intangibles (2022 - 2023) Analysis & Trends
NewAmsterdam Pharma has disclosed Intangibles across 2 years of filings, most recently posting $88887.8 for Q2 2023.
- Intangibles for Q2 2023 came in at $88887.8, changed N/A year-over-year; the trailing twelve-month figure through Jun 2023 was $88887.8 (changed N/A YoY), and the FY2022 annual result was $84.8 million, changed N/A from the prior year.
- Intangibles came in at $88887.8 for Q2 2023 at NewAmsterdam Pharma, down from $84.8 million in the prior quarter.
- In the past five years, Intangibles ranged from a high of $84.8 million in Q4 2022 to a low of $88887.8 in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4.41 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 30.30 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 418.50 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 7.73 Mn |
| 10 | NewAmsterdam Pharma | 3.63 Bn | 3.63 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 88,887.81 |
| Dec 31, 2022 | 84.84 Mn |